Overview

A Study to Explore the Effect of Acid-reducing Agents

Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.
Phase:
Phase 1
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Famotidine
Pantoprazole